Biased by design? Clinical trials and patient benefit in oncology

被引：3
作者：
Pantziarka, Pan [1 ,2 ]
Verbaanderd, Ciska [1 ,3 ]
Meheus, Lydie [1 ]
机构：
[1] Anticanc Fund, 1853 Strombeek Bever, Brussels, Belgium
[2] George Pantziarka TP53 Trust, London, England
[3] Katholieke Univ Leuven, Clin Pharmacol & Pharmacotherapy, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium
来源：
FUTURE ONCOLOGY | 2020年 / 16卷 / 03期
关键词：
clinical trial design; drug development; drug registration; patient benefit; risks of bias; SCIENTIFIC ADVICE; CANCER; DRUGS; MAGNITUDE; THERAPIES; SURVIVAL; APPROVAL;
D O I：
10.2217/fon-2019-0763
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：4419 / 4423
页数：5
相关论文
共 50 条
[31]   Design for immuno-oncology clinical trials enrolling both responders and nonresponders [J].
Xu, Zhenzhen ;
Zhu, Bin ;
Park, Yongsoek .
STATISTICS IN MEDICINE, 2020, 39 (27) :3914-3936
[32]   Leveraging external data in the design and analysis of clinical trials in neuro-oncology [J].
Rahman, Rifaquat ;
Ventz, Steffen ;
McDunn, Jon ;
Louv, Bill ;
Reyes-Rivera, Irmarie ;
Polley, Mei-Yin C. ;
Merchant, Fahar ;
Abrey, Lauren E. ;
Allen, Joshua E. ;
Aguilar, Laura K. ;
Aguilar-Cordova, Estuardo ;
Arons, David ;
Tanner, Kirk ;
Bagley, Stephen ;
Khasraw, Mustafa ;
Cloughesy, Timothy ;
Wen, Patrick Y. ;
Alexander, Brian M. ;
Trippa, Lorenzo ;
Roche, F. Hoffmann-La ;
Aguilar-Cordova, E. ;
Tanner, K. .
LANCET ONCOLOGY, 2021, 22 (10) :E456-E465
[33]   Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials [J].
Khan, Adam ;
Khan, Hassan ;
Hughes, Griffin K. ;
Ladd, Chase ;
Mcintire, Ryan ;
Gardner, Brooke ;
Pena, Andriana M. ;
Schoutko, Abigail ;
Tuia, Jordan ;
Minley, Kirstien ;
Haslam, Alyson ;
Prasad, Vinay ;
Vassar, Matt .
CANCER MEDICINE, 2024, 13 (09)
[34]   Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials [J].
Gardner, Taylor ;
Duncan, Jacob ;
Hughes, Griffin K. ;
Mcintire, Ryan ;
Gardner, Brooke ;
Pena, Andriana ;
Ladd, Chase ;
Snider, Kelsey ;
Ottwell, Ryan ;
Tuia, Jordan ;
Haslam, Alyson ;
Prasad, Vinay ;
Vassar, Matt .
MELANOMA MANAGEMENT, 2025, 12 (01)
[35]   A two-stage patient enrichment adaptive design in phase II oncology trials [J].
Song, James X. .
CONTEMPORARY CLINICAL TRIALS, 2014, 37 (01) :148-154
[36]   Evaluation of spin in oncology clinical trials [J].
Wayant, C. ;
Margalski, D. ;
Vaughn, K. ;
Vassar, M. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 144
[37]   Clinical Trials and Personalized Medicine in Oncology? [J].
Arnold, Dirk ;
Bokemeyer, Carsten .
ONKOLOGIE, 2010, 33 :25-29
[38]   Clinical trials in the era of personalized oncology [J].
Maitland, Michael L. ;
Schilsky, Richard L. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (06) :365-381
[39]   The future of clinical trials in urological oncology [J].
Narayan, Vikram M. ;
Dahm, Philipp .
NATURE REVIEWS UROLOGY, 2019, 16 (12) :722-733
[40]   The Use of Patient-Reported Outcome Measures in Phase I Oncology Clinical Trials [J].
Coleman, Robert L. ;
Beck, J. Thaddeus ;
Baranda, Joaquina C. ;
Jacobs, Ira ;
Smoyer, Karen E. ;
Lee, Lauren J. ;
Askerova, Zemfira ;
McGinnis, Justin ;
Ganti, Apar Kishor .
ONCOLOGY, 2021, :444-453
12345